NOVARTIS AG DRNNOVARTIS AG DRNNOVARTIS AG DRN

NOVARTIS AG DRN

No trades
See on Supercharts

Key facts today


DA Davidson has downgraded Novartis (NOVN) from a 'Buy' rating to 'Neutral', with a new price target set at $120.
In 2020, Novartis settled claims for over $600 million regarding its speaker program, accused of bribing doctors to prescribe its drugs, and improved its compliance framework.
Analyze the impactAnalyze the impact
Market capitalization
‪1.26 T‬BRL
35.577BRL
‪71.79 B‬BRL
‪302.49 B‬BRL
‪1.70 B‬
Beta (1Y)
−0.15

About NOVARTIS N


CEO
Vasant Narasimhan
Headquarters
Basel
Founded
1996
ISIN
BRN1VSBDR006
FIGI
BBG00XX9KCR3
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.20%
Maturity date
Aug 14, 2050
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.62%
Maturity date
Sep 21, 2042
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
5.58%
Maturity date
Nov 20, 2045
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.42%
Maturity date
May 6, 2044
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.38%
Maturity date
Sep 18, 2054
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
4.89%
Maturity date
Sep 18, 2034
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
4.62%
Maturity date
Aug 14, 2030
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.51%
Maturity date
Sep 18, 2031
XPNC
NOVARTIS CAPITAL 15/25
Yield to maturity
4.46%
Maturity date
Nov 20, 2025
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.39%
Maturity date
Sep 18, 2029
US66989HAN8
NOVARTIS CAPITAL 17/27
Yield to maturity
4.23%
Maturity date
May 17, 2027

See all N1VS34 bonds